Opthea company information, Employees & Contact Information

Opthea parts with CEO, lays off over 80% of company Ophthalmology Times

Opthea Limited Reports Negative Results from COAST Phase 3 Trial, Assessing Impact on Financial Solvency and Future Strategies Nasdaq

Opthea Announces Termination of ShORe and COAST Trials of Sozinibercept HCPLive

Opthea lays off 65% of staff after back-to-back phase 3 eye disease flops Fierce Biotech

Opthea to lay off approximately 65% of company Ophthalmology Times

Sozinibercept for Wet AMD Misses Primary Endpoint in Phase 3 COAST Trial HCPLive

Opthea announces decision to discontinue wet-AMD clinical trials BiotechDispatch

Opthea Completes COAST Final Week 52 Patient Visit BioMelbourne Network

Health Check: Stuck in biotech’s ‘death zone’, Opthea and Patrys check in on the sat phone Stockhead

Opthea to lay off 80% of workforce amid executive cuts Eyes On Eyecare

Opthea on the brink after Phase-3 failure Forbes Australia

Opthea discontinues COAST and ShORe trials in wet AMD Ophthalmology Times

EX-99.1 SEC.gov

Opthea discontinues development of sozinibercept in wet AMD Healio

Health Check: Opthea investors have $80m less to fight for after cash-burning quarter Stockhead

Opthea updates investors, confirming significant staff reduction BiotechDispatch

Opthea, still reeling from eye disease flops, ramps up cuts to 85% of staff and loses CEO Fierce Biotech

Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint Ophthalmology Times

Opthea now managing the fallout of clinical trial result BiotechDispatch

Opthea scraps wet AMD program after eye drug loses out to Lucentis in latest phase 3 fail Fierce Biotech

Opthea's eye disease drug defeated by Eylea in phase 3, leaving biotech to mull future Fierce Biotech

Opthea completes enrollment in two phase 3 trials of sozinibercept in wet AMD Healio

Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market Stock Titan

Opthea completes enrollment for sozinibercept (OPT-302) trials in pivotal Phase 3 program Optometry Times

Race Oncology appoints Opthea founder to its board BiotechDispatch

Opthea Announces Executive Leadership Changes and Senior Hires VisionMonday.com

Opthea Limited: Major Catalyst In Early 2025 For Complementary Eye Disease Candidate Seeking Alpha

Opthea: Small Australian Company Aiming To Upend The Wet AMD Market (NASDAQ:OPT) Seeking Alpha

Opthea highlights latest phase 3 trials for sozinibercept Ophthalmology Times

Treatment Approaches for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema The American Journal of Managed Care® (AJMC®)

Phil King’s Regal writes Opthea to zero and backs off risky bets AFR

Opthea (OPT) Stock Price, News & Analysis MarketBeat

Opthea announces leadership transition with the appointment of US-based executives BiotechDispatch

Opthea's Lucentis/VEGF 'trap' combo outshines Lucentis alone in wet AMD Fierce Biotech

Regal Partners digests impact of Opthea failure MoneyManagement.com.au

Opthea discontinuing nAMD trials insightnews.com.au

End in sight as Opthea looks to be key player in US$10 billion wet AMD market Stockhead

Health Check: With its last patient treated, Opthea eyes pending results of do-or-die trial Stockhead

Regal FUM rebounds after Opthea losses MoneyManagement.com.au

Opthea solvency in question as trial failure trips $1bn trigger The Australian

Opthea solvency in spotlight after ‘negative’ Phase 3 AMD trial result insightnews.com.au

Opthea receives additional funding under development funding agreement BiotechDispatch

Is Opthea a good investment? moneymag.com.au

Opthea (ASX:OPT) shares a business update with investors Rask Media

New CEO as Opthea reveals leadership reshuffle insightnews.com.au

Clock’s Ticking: In 24 hours we’ll know if Opthea’s DME clinical trial was successful Stockhead

How Opthea became a $1 billion stock in a month, and analysts reckon there's still more to come Stockhead